

# Edwin Choy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2345121/publications.pdf>

Version: 2024-02-01

160  
papers

9,464  
citations

41627

51  
h-index

51423

90  
g-index

167  
all docs

167  
docs citations

167  
times ranked

13387  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Artificial intelligence applied to musculoskeletal oncology: a systematic review. <i>Skeletal Radiology</i> , 2022, 51, 245-256.   | 1.2  | 11        |
| 2  | Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 1291-1300.  | 0.8  | 24        |
| 3  | Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement. <i>Journal of Oncology</i> , 2022, 2022, 1-9.   | 0.6  | 6         |
| 4  | Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcoma. <i>Communications Biology</i> , 2022, 5, 213.  | 2.0  | 10        |
| 5  | OUP accepted manuscript. <i>Oncologist</i> , 2022, , .   | 1.9  | 0         |
| 6  | EWSR1-ATF1 dependent 3D connectivity regulates oncogenic and differentiation programs in Clear Cell Sarcoma. <i>Nature Communications</i> , 2022, 13, 2267.  | 5.8  | 18        |
| 7  | Outcomes following preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): A report from Children's Oncology Group (COG) and NRG Oncology.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11504-11504.  | 0.8  | 6         |
| 8  | Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11523-11523.  | 0.8  | 4         |
| 9  | Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. <i>Nature Communications</i> , 2022, 13, .   | 5.8  | 51        |
| 10 | Abstract CT185: A phase I dose escalation study of a tegavivint (BC2059) a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumors. <i>Cancer Research</i> , 2022, 82, CT185-CT185.   | 0.4  | 1         |
| 11 | A phase 1b lead-in to a randomized phase 2 trial of lurbinectedin plus doxorubicin in leiomyosarcoma (LMS).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS11592-TPS11592.  | 0.8  | 2         |
| 12 | Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e23507-e23507.  | 0.8  | 1         |
| 13 | Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 815-833.  | 2.3  | 445       |
| 14 | Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. <i>Nature Medicine</i> , 2021, 27, 289-300.   | 15.2 | 64        |
| 15 | Outcomes in the dedifferentiated liposarcoma cohort of SAR-096, a phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11515-11515.                      | 0.8  | 0         |
| 16 | A phase II trial of sitravatinib, a multireceptor tyrosine kinase inhibitor, in patients with advanced well-differentiated/dedifferentiated liposarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11513-11513.   | 0.8  | 1         |
| 17 | P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11503-11503.  | 0.8  | 6         |
| 18 | Preliminary results of phase 2 trial of preoperative image guided intensity modulated proton radiation therapy (IMPT) with simultaneously integrated boost (SIB) to the high-risk margin for retroperitoneal sarcomas (RPS).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11550-11550. | 0.8  | 5         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies. <i>Life Science Alliance</i> , 2021, 4, e202000808.   | 1.3 | 18        |
| 20 | Percutaneous Cryoablation: Safety and Efficacy for Pain Palliation of Metastases to Pleura and Chest Wall. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 294-300.   | 0.2 | 11        |
| 21 | LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma. <i>Cell Reports</i> , 2020, 30, 4567-4583.e5.   | 2.9 | 20        |
| 22 | Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1110-1122. | 5.1 | 63        |
| 23 | MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma. <i>Scientific Reports</i> , 2020, 10, 4409.  | 1.6 | 9         |
| 24 | Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity. <i>Journal of Surgical Oncology</i> , 2020, 122, 877-883.   | 0.8 | 24        |
| 25 | Programmed Death Ligand 1 and Immune Cell Infiltrates in Solitary Fibrous Tumors of the Pleura. <i>Annals of Thoracic Surgery</i> , 2020, 112, 1862-1869.   | 0.7 | 1         |
| 26 | Chondroblastoma Expresses RANKL by RNA In Situ Hybridization and May Respond to Denosumab Therapy. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1581-1590.   | 2.1 | 5         |
| 27 | Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): Report of LMS cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11559-11559.  | 0.8 | 13        |
| 28 | NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1604-1612.  | 2.3 | 175       |
| 29 | Conditional survival of patients with nonmetastatic bone osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23511-e23511.  | 0.8 | 1         |
| 30 | Updated 5-year local control (LC), metastasis-free survival (MFS), and overall survival (OS) data from a phase I study of nilotinib plus radiation (RT) in high-risk chordoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23505-e23505.  | 0.8 | 0         |
| 31 | Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1719-1729.  | 5.1 | 143       |
| 32 | Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. <i>Radiotherapy and Oncology</i> , 2019, 137, 61-70.   | 0.3 | 54        |
| 33 | Spindle and Round Cell Sarcoma With EWSR1-PATZ1 Gene Fusion. <i>American Journal of Surgical Pathology</i> , 2019, 43, 220-228.   | 2.1 | 57        |
| 34 | Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution. <i>Sarcoma</i> , 2019, 2019, 1-10.   | 0.7 | 23        |
| 35 | Preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): A report from Children's Oncology Group (COG) and NRG Oncology.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11002-11002.  | 0.8 | 6         |
| 36 | A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1<sup>+</sup> soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11011-11011.  | 0.8 | 10        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Results of the dose-finding phase of ARST 1321 from the Children's Oncology Group and NRG Oncology: Neoadjuvant chemoradiation or radiation therapy +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcomas.. Journal of Clinical Oncology, 2019, 37, 11070-11070. | 0.8 | 3         |
| 38 | Clinicopathologic characteristics of poorly differentiated chordoma. Modern Pathology, 2018, 31, 1237-1245.   | 2.9 | 102       |
| 39 | Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncology, 2018, 4, 814.  | 3.4 | 26        |
| 40 | Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience. Oncologist, 2018, 23, 234-242.  | 1.9 | 54        |
| 41 | CDK4 expression in chordoma: A potential therapeutic target. Journal of Orthopaedic Research, 2018, 36, 1581-1589.  | 1.2 | 21        |
| 42 | Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma. Medicine (United States), 2018, 97, e13321.  | 0.4 | 8         |
| 43 | Extraskeletal osteosarcoma: A large series treated at a single institution. Rare Tumors, 2018, 10, 203636131774965.   | 0.3 | 13        |
| 44 | SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Sarcoma, 2018, 2018, 1-9.                        | 0.7 | 13        |
| 45 | Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. World Journal of Surgical Oncology, 2018, 16, 191.  | 0.8 | 39        |
| 46 | A Phase 1 Study of Nilotinib Plus Radiation in High-Risk Chordoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1496-1504.   | 0.4 | 13        |
| 47 | Phase 2 results of selinexor in advanced de-differentiated (DDLs) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.. Journal of Clinical Oncology, 2018, 36, 11512-11512.   | 0.8 | 15        |
| 48 | Nodal involvement and survival in synovial, clear cell, angio, rhabdo, and epithelioid sarcoma.. Journal of Clinical Oncology, 2018, 36, 11567-11567.   | 0.8 | 2         |
| 49 | Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells. Oncotarget, 2018, 9, 13154-13166.   | 0.8 | 13        |
| 50 | Outcomes of intermediate-high grade retroperitoneal sarcomas.. Journal of Clinical Oncology, 2018, 36, e23562-e23562.   | 0.8 | 0         |
| 51 | miRâ€15b modulates multidrug resistance in human osteosarcoma <i>in vitro</i> and <i>in vivo</i>. Molecular Oncology, 2017, 11, 151-166.   | 2.1 | 47        |
| 52 | Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Advances in Radiation Oncology, 2017, 2, 85-93.                                    | 0.6 | 57        |
| 53 | Autophagy as a potential target for sarcoma treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 40-50.   | 3.3 | 19        |
| 54 | Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosis. Cellular Oncology (Dordrecht), 2017, 40, 209-218.   | 2.1 | 30        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. <i>Scientific Reports</i> , 2017, 7, 43941.   | 1.6 | 13        |
| 56 | Expression and Therapeutic Potential of SOX9 in Chordoma. <i>Clinical Cancer Research</i> , 2017, 23, 5176-5186.  | 3.2 | 40        |
| 57 | Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy. <i>Oncologist</i> , 2017, 22, 1265-1270.                       | 1.9 | 24        |
| 58 | Frequency and Risk Factors for Additional Lesions in the Axial Spine in Subjects With Chordoma. <i>Spine</i> , 2017, 42, E37-E40.   | 1.0 | 10        |
| 59 | Application of metabolomics in sarcoma: From biomarkers to therapeutic targets. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 116, 1-10.   | 2.0 | 12        |
| 60 | Therapeutic applications of histone deacetylase inhibitors in sarcoma. <i>Cancer Treatment Reviews</i> , 2017, 59, 33-45.   | 3.4 | 49        |
| 61 | An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. <i>Journal of Hematology and Oncology</i> , 2017, 10, 107.                              | 6.9 | 38        |
| 62 | Updated Outcome and Analysis of Tumor Response in Mobile Spine and Sacral Chordoma Treated With Definitive High-Dose Photon/Proton Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 254-262. | 0.4 | 69        |
| 63 | Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. <i>Cancer</i> , 2017, 123, 90-97.   | 2.0 | 101       |
| 64 | Phase III study of adoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11000-11000.   | 0.8 | 31        |
| 65 | Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS11082-TPS11082.                                     | 0.8 | 1         |
| 66 | Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates. <i>PLoS ONE</i> , 2017, 12, e0188859.   | 1.1 | 10        |
| 67 | Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. <i>Oncotarget</i> , 2017, 8, 30276-30287.  | 0.8 | 69        |
| 68 | SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. <i>Cancer</i> , 2016, 122, 868-874.  | 2.0 | 80        |
| 69 | Prognostic factors in alveolar soft part sarcoma: A SEER analysis. <i>Journal of Surgical Oncology</i> , 2016, 113, 581-586.  | 0.8 | 50        |
| 70 | Clinical outcomes for patients after surgery and radiation therapy for mesenchymal chondrosarcomas. <i>Journal of Surgical Oncology</i> , 2016, 114, 982-986.   | 0.8 | 11        |
| 71 | Differences in sex distribution, anatomic location and MR imaging appearance of pediatric compared to adult chordomas. <i>BMC Medical Imaging</i> , 2016, 16, 53.   | 1.4 | 22        |
| 72 | Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. <i>Scientific Reports</i> , 2016, 6, 25239.   | 1.6 | 41        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | The Width of the Surgical Margin Does Not Influence Outcomes in Extremity and Truncal Soft Tissue Sarcoma Treated With Radiotherapy. <i>Oncologist</i> , 2016, 21, 1269-1276.  | 1.9  | 41        |
| 74 | Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1691-1701.            | 1.9  | 31        |
| 75 | Case 26-2016. <i>New England Journal of Medicine</i> , 2016, 375, 779-788.   | 13.9 | 0         |
| 76 | PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3898-3905.  | 0.8  | 151       |
| 77 | Preoperative radiation therapy combined with radical surgical resection is associated with a lower rate of local recurrence when treating unifocal, primary retroperitoneal liposarcoma. <i>Journal of Surgical Oncology</i> , 2016, 114, 814-820. | 0.8  | 27        |
| 78 | Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats. <i>Scientific Reports</i> , 2016, 6, 25659.  | 1.6  | 14        |
| 79 | TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. <i>Nature Communications</i> , 2016, 7, 12609.   | 5.8  | 73        |
| 80 | Clinical and biological significance of PIM1 kinase in osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2016, 34, 1185-1194.   | 1.2  | 18        |
| 81 | NVPâ€AE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting Pâ€glycoprotein (PGP1) function. <i>British Journal of Pharmacology</i> , 2016, 173, 613-626.   | 2.7  | 26        |
| 82 | Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma. <i>Cancer Letters</i> , 2016, 373, 109-118.  | 3.2  | 30        |
| 83 | Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1629-1637.   | 6.3  | 610       |
| 84 | Targeting protein kinases to reverse multidrug resistance in sarcoma. <i>Cancer Treatment Reviews</i> , 2016, 43, 8-18.  | 3.4  | 19        |
| 85 | p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 349-356.   | 1.1  | 37        |
| 86 | High-Dose Proton Beamâ€Based Radiation Therapy in the Management of Extracranial Chondrosarcomas. <i>International Journal of Particle Therapy</i> , 2016, 3, 373-381.  | 0.9  | 7         |
| 87 | Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance. <i>Oncotarget</i> , 2016, 7, 83502-83513.   | 0.8  | 67        |
| 88 | Prognostic factors in osteosarcoma: A single institution study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22503-e22503.  | 0.8  | 0         |
| 89 | Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer. <i>Pharmaceutical Research</i> , 2015, 32, 2097-2109.  | 1.7  | 75        |
| 90 | Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. <i>Cancer</i> , 2015, 121, 1223-1230.   | 2.0  | 54        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Tibial stress reaction presenting as bilateral shin pain in a man taking denosumab for giant cell tumor of the bone. <i>Bone</i> , 2015, 81, 31-35.  | 1.4 | 5         |
| 92  | CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. <i>Scientific Reports</i> , 2015, 5, 11365.  | 1.6 | 71        |
| 93  | NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. <i>Gynecologic Oncology</i> , 2015, 137, 134-142.  | 0.6 | 10        |
| 94  | MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. <i>Scientific Reports</i> , 2015, 5, 8509.  | 1.6 | 109       |
| 95  | <i>TP53</i> mutations emerge in circulating cell-free DNA obtained from patients undergoing treatment with the HDM2 antagonist SAR405838.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2515-2515.  | 0.8 | 4         |
| 96  | MicroRNA-155 expression is independently predictive of outcome in chordoma. <i>Oncotarget</i> , 2015, 6, 9125-9139.  | 0.8 | 38        |
| 97  | Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. <i>Oncotarget</i> , 2015, 6, 11139-11149.  | 0.8 | 89        |
| 98  | The emerging roles and therapeutic potential of microRNAs (miRs) in liposarcoma. <i>Discovery Medicine</i> , 2015, 20, 311-24.   | 0.5 | 9         |
| 99  | Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma. <i>PLoS ONE</i> , 2014, 9, e93996.  | 1.1 | 19        |
| 100 | Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential. <i>Oncolmmunology</i> , 2014, 3, e954467.   | 2.1 | 14        |
| 101 | Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. <i>Cancer</i> , 2014, 120, 3676-3682.   | 2.0 | 62        |
| 102 | Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. <i>BMC Cancer</i> , 2014, 14, 813.  | 1.1 | 132       |
| 103 | Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma. <i>Journal of Orthopaedic Research</i> , 2014, 32, 695-701.   | 1.2 | 40        |
| 104 | Sarcoma after 5 years of progression-free survival: Lessons from the French Sarcoma Group. <i>Cancer</i> , 2014, 120, 2942-2943.   | 2.0 | 3         |
| 105 | A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. <i>BMC Cancer</i> , 2014, 14, 681.  | 1.1 | 25        |
| 106 | Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. <i>Cancer Letters</i> , 2014, 342, 104-112.  | 3.2 | 45        |
| 107 | Programmed Cell Death Ligand 1 Expression in Osteosarcoma. <i>Cancer Immunology Research</i> , 2014, 2, 690-698.   | 1.6 | 182       |
| 108 | Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. <i>European Journal of Cancer</i> , 2014, 50, 981-986. | 1.3 | 29        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Biosimilar Safety Considerations in Clinical Practice. <i>Seminars in Oncology</i> , 2014, 41, S3-S14.  | 0.8 | 67        |
| 110 | Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1. <i>PLoS ONE</i> , 2014, 9, e101283.   | 1.1 | 72        |
| 111 | Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 901-908.      | 5.1 | 487       |
| 112 | Role of Epigenetic Modulation for the Treatment of Sarcoma. <i>Current Treatment Options in Oncology</i> , 2013, 14, 454-464.   | 1.3 | 17        |
| 113 | Update in Treatment and Targets in Ewing Sarcoma. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1007-1019.  | 0.9 | 13        |
| 114 | Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year single institution retrospective study. <i>European Journal of Cancer</i> , 2013, 49, 875-883.                                    | 1.3 | 61        |
| 115 | Targeting hedgehog-GLI2 pathway in osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2013, 31, 502-509.  | 1.2 | 38        |
| 116 | β-Catenin Mutation Status and Outcomes in Sporadic Desmoid Tumors. <i>Oncologist</i> , 2013, 18, 1043-1049.   | 1.9 | 113       |
| 117 | Tissue Microarray Immunohistochemical Detection of Brachyury Is Not a Prognostic Indicator in Chordoma. <i>PLoS ONE</i> , 2013, 8, e75851.  | 1.1 | 34        |
| 118 | Abstract LB-167: Phase I dose escalation study of abexinostat and doxorubicin in patients with metastatic sarcomas. , 2013, , .   |     | 1         |
| 119 | Prolonged survival and disease control in the academic phase II trial of regorafenib in GIST: Response based on genotype. <i>Journal of Clinical Oncology</i> , 2013, 31, 10511-10511.  | 0.8 | 6         |
| 120 | Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation. <i>Clinical Cancer Research</i> , 2012, 18, 4580-4588.                                     | 3.2 | 55        |
| 121 | Synthesis and Evaluation of (2-(4-Methoxyphenyl)-4-quinolinyloxy)(2-piperidinyl)methanol (NSC23925) Isomers To Reverse Multidrug Resistance in Cancer. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3113-3121.                   | 2.9 | 42        |
| 122 | Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2401-2407. | 0.8 | 232       |
| 123 | Desmoid Tumor: Analysis of Prognostic Factors and Outcomes in a Surgical Series. <i>Annals of Surgical Oncology</i> , 2012, 19, 4028-4035.  | 0.7 | 107       |
| 124 | Establishment and characterization of a novel chordoma cell line: CH22. <i>Journal of Orthopaedic Research</i> , 2012, 30, 1666-1673.   | 1.2 | 37        |
| 125 | High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide 3-kinase and other oncogenes. <i>Cancer</i> , 2012, 118, 2905-2914.  | 2.0 | 63        |
| 126 | Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. <i>Cancer</i> , 2012, 118, 3758-3765.   | 2.0 | 76        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors. <i>Cancer</i> , 2012, 118, 5894-5902.   | 2.0 | 140       |
| 128 | Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year follow-up study. <i>Journal of Clinical Oncology</i> , 2012, 30, 10058-10058.   | 0.8 | 0         |
| 129 | Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1081-1090.   | 0.4 | 77        |
| 130 | Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. <i>Anti-Cancer Drugs</i> , 2011, 22, 444-453.   | 0.7 | 32        |
| 131 | Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 439-446.  | 1.1 | 37        |
| 132 | ROCK1 as a potential therapeutic target in osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2011, 29, 1259-1266.  | 1.2 | 73        |
| 133 | Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. <i>Cancer</i> , 2011, 117, 4522-4530.   | 2.0 | 149       |
| 134 | MicroRNA-199a-3p Is Downregulated in Human Osteosarcoma and Regulates Cell Proliferation and Migration. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1337-1345.   | 1.9 | 229       |
| 135 | Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. <i>Anticancer Research</i> , 2011, 31, 1115-23.  | 0.5 | 19        |
| 136 | Blockage of Stat3 With CDDO-Me Inhibits Tumor Cell Growth in Chordoma. <i>Spine</i> , 2010, 35, 1668-1675.  | 1.0 | 40        |
| 137 | Characterization and Analysis of Human Chordoma Cell Lines. <i>Spine</i> , 2010, 35, 1257-1264.   | 1.0 | 30        |
| 138 | Proton-Beam, Intensity-Modulated, and/or Intraoperative Electron Radiation Therapy Combined with Aggressive Anterior Surgical Resection for Retroperitoneal Sarcomas. <i>Annals of Surgical Oncology</i> , 2010, 17, 1515-1529.               | 0.7 | 97        |
| 139 | Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. <i>BMC Cancer</i> , 2010, 10, 187.   | 1.1 | 51        |
| 140 | Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. <i>Journal of Orthopaedic Research</i> , 2010, 28, 746-752.   | 1.2 | 83        |
| 141 | Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated Stat3 correlates with poor prognosis. <i>Journal of Orthopaedic Research</i> , 2010, 28, 971-978. | 1.2 | 66        |
| 142 | Cyclin G-Associated Kinase Is Necessary for Osteosarcoma Cell Proliferation and Receptor Trafficking. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3342-3350.  | 1.9 | 34        |
| 143 | Multidrug Resistance Reversal Agent, NSC77037, Identified with a Cell-Based Screening Assay. <i>Journal of Biomolecular Screening</i> , 2010, 15, 287-296.  | 2.6 | 28        |
| 144 | Effects of Siltuximab on the IL-6-Induced Signaling Pathway in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5759-5769.   | 3.2 | 86        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 145 | The kinase Mirk is a potential therapeutic target in osteosarcoma. <i>Carcinogenesis</i> , 2010, 31, 552-558.  | 1.3  | 44        |
| 146 | Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. <i>Cancer Letters</i> , 2010, 293, 220-229.   | 3.2  | 56        |
| 147 | Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma. <i>PLoS ONE</i> , 2010, 5, e10764.  | 1.1  | 128       |
| 148 | ZNF93 Increases Resistance to ET-743 (Trabectedin; Yondelis®) and PM00104 (Zalypsis®) in Human Cancer Cell Lines. <i>PLoS ONE</i> , 2009, 4, e6967.  | 1.1  | 15        |
| 149 | NSC23925, Identified in a High-Throughput Cell-Based Screen, Reverses Multidrug Resistance. <i>PLoS ONE</i> , 2009, 4, e7415.  | 1.1  | 40        |
| 150 | Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2122-2130. | 1.9  | 76        |
| 151 | A novel target for treatment of chordoma: signal transducers and activators of transcription 3. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2597-2605.   | 1.9  | 57        |
| 152 | The role of the <i>CD58</i> locus in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5264-5269.  | 3.3  | 185       |
| 153 | Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1121-1129.  | 1.1  | 17        |
| 154 | Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. <i>Annals of Surgical Oncology</i> , 2009, 16, 1356-1363.   | 0.7  | 71        |
| 155 | Case 36-2009. <i>New England Journal of Medicine</i> , 2009, 361, 2080-2087.   | 13.9 | 4         |
| 156 | Genetic Analysis of Human Traits In Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines. <i>PLoS Genetics</i> , 2008, 4, e1000287.   | 1.5  | 200       |
| 157 | Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2377-2385.                         | 1.9  | 28        |
| 158 | Admixture Mapping of an Allele Affecting Interleukin 6 Soluble Receptor and Interleukin 6 Levels. <i>American Journal of Human Genetics</i> , 2007, 80, 716-726.   | 2.6  | 160       |
| 159 | Endomembrane Trafficking of Ras. <i>Cell</i> , 1999, 98, 69-80.  | 13.5 | 713       |
| 160 | Mammalian Prenylcysteine Carboxyl Methyltransferase Is in the Endoplasmic Reticulum. <i>Journal of Biological Chemistry</i> , 1998, 273, 15030-15034.  | 1.6  | 262       |